On August 19, China Cord Blood Corporation (NYSE:CO), China’s top umbilical cord blood storage services provider, released its preliminary unaudited financial results for …
In a research note issued this morning, Roth Capital analyst Scott Henry maintained a Buy rating on China Cord Blood Corporation (CO) and raised his price target to $6.00 (from $5.
